Skip to main content
. Author manuscript; available in PMC: 2013 Nov 26.
Published in final edited form as: Vaccine. 2012 Oct 2;30(50):7265–7270. doi: 10.1016/j.vaccine.2012.09.058

Fig. 4.

Fig. 4

Hemagglutinin inhibition (HAI) titers in RM. Eight SIV-vaccinated RM (black) and two vector control RM (white) that controlled SIV to below detectable levels were subsequently immunized with Ad5 [E1-, E2b-]-HA on days 119 and 147. Sera were assessed for the development of H1N1 neutralizing antibody activity 30 days after the first H1N1 vaccination (day 147). All 10 RM vaccinated with Ad5 [E1-, E2b-]-HA seroconverted. The RM were then boosted with Ad5 [E1-, E2b-]-HA on day 147 and HAI titers were assessed 2 weeks later (day 161). The boost increased HAI in both groups, averaging 1:580 ± 120 (SEM) in SIV vaccinated RM and 1:960 ± 320 in SIV control RM.

HHS Vulnerability Disclosure